GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptorum Group Ltd (NAS:APM) » Definitions » Cash Flow from Financing

Aptorum Group (Aptorum Group) Cash Flow from Financing : $4.58 Mil (TTM As of Jun. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Aptorum Group Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the six months ended in Jun. 2023, Aptorum Group received $1.58 Mil more from issuing new shares than it paid to buy back shares. It spent $0.50 Mil paying down its debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $0.02 Mil on other financial activities. In all, Aptorum Group earned $1.09 Mil on financial activities for the six months ended in Jun. 2023.


Aptorum Group Cash Flow from Financing Historical Data

The historical data trend for Aptorum Group's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptorum Group Cash Flow from Financing Chart

Aptorum Group Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cash Flow from Financing
Get a 7-Day Free Trial 25.48 -7.32 12.42 2.78 6.63

Aptorum Group Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.20 -0.42 3.14 3.49 1.09

Aptorum Group Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Aptorum Group's Cash from Financing for the fiscal year that ended in Dec. 2022 is calculated as:

Aptorum Group's Cash from Financing for the quarter that ended in Jun. 2023 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $4.58 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aptorum Group  (NAS:APM) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Aptorum Group's issuance of stock for the six months ended in Jun. 2023 was $1.58 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Aptorum Group's repurchase of stock for the six months ended in Jun. 2023 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Aptorum Group's net issuance of debt for the six months ended in Jun. 2023 was $-0.50 Mil. Aptorum Group spent $0.50 Mil paying down its debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Aptorum Group's net issuance of preferred for the six months ended in Jun. 2023 was $0.00 Mil. Aptorum Group paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Aptorum Group's cash flow for dividends for the six months ended in Jun. 2023 was $0.00 Mil. Aptorum Group received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Aptorum Group's other financing for the six months ended in Jun. 2023 was $0.02 Mil. Aptorum Group received $0.02 Mil on other financial activities.


Aptorum Group Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Aptorum Group's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Aptorum Group (Aptorum Group) Business Description

Traded in Other Exchanges
N/A
Address
17 Hanover Square, London, GBR, W1S 1BN
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.

Aptorum Group (Aptorum Group) Headlines

From GuruFocus